Structural Heart

This structural heart channel includes news, videos, podcasts and other content related to diagnosis and treatment of structural heart disease. Topics covered include heart valve repair and replacement, transcatheter aortic valve replacement (TAVR), transcatheter mitral valve replacement (TMVR), transcatheter tricuspid valve replacement (TTVR), left atrial appendage (LAA) occlusion, heart failure interventional device therapies, and closing holes in the heart using, including occlusion of atrial septal defects (ASDs), ventricular septal defects (VSDs) and patent foramen ovales (PFOs).

News | Structural Heart

November 9, 2021 — An economic analysis of data from PARTNER 3, a randomized trial comparing transcatheter aortic valve ...

Home November 09, 2021
Home
News | Left Atrial Appendage (LAA) Occluders

November 8, 2021 – SWISS-APERO is the first randomized clinical trial comparing the Abbott Amulet left atrial appendage ...

Home November 08, 2021
Home
News | Structural Heart

November 8, 2021 — Results from a clinical trial of the Edwards Lifesciences Evoque transcatheter tricuspid valve ...

Home November 08, 2021
Home
The FDA cleared the world's first photon-counting computed tomography (CT) scanner, the Siemens Naeotom Alpha, in late September. This new technology will likely change the future direction of CT. Biosense Webster also announced the first cases using its Heliostar radiofrequency balloon ablation catheter were completed in September. Both were among the top stories in October.
Feature | By Dave Fornell, DAIC Editor

November 1, 2021 — Here is the list of the most popular content on the Diagnostic and Interventional Cardiology (DAIC) ...

Home November 01, 2021
Home
Videos | Structural Heart

Dr. Neil Moat, MBBS, chief medical officer of Abbott's structural heart business, was a cardiac surgeon specializing in ...

Home October 15, 2021
Home
News | Computed Tomography (CT)

October 14, 2021 — Cardiac computed tomography angiography (CTA) derived left atrium emptying fraction (LAEF) improves ...

Home October 14, 2021
Home
Videos | Structural Heart

Tiberio Frisoli, M.D., interventional structural cardiologist, senior staff physician, Henry Ford Hospital, explains how ...

Home October 14, 2021
Home
News | Cath Lab

October 6, 2021 — Boston Scientific Corp. announced it entered into a definitive agreement to acquire Baylis Medical ...

Home October 06, 2021
Home
Two of the top technology headlines this past month was the FDA clearance of the Abbott Portico transcatheter aortic valve replacement (TAVR) device, and the first women to receive a Carmat artificial heart.
Feature | BY Dave Fornell, DAIC Editor

October 6, 2021 — Here is the list of the most popular content on the Diagnostic and Interventional Cardiology (DAIC) ...

Home October 06, 2021
Home
News | Structural Heart Occluders

October 4, 2021 — U.S. Food and Drug Administration (FDA) has cleared the Abbott Amplatzer Talisman PFO Occlusion System ...

Home October 04, 2021
Home
Videos | Stem Cell Therapies

Mechanical engineering Professor Nathan Sniadecki, associate chair for research and infrastructure, mechanical ...

Home October 04, 2021
Home
Videos | Structural Heart

Tom Jones, M.D., director, cardiac cath labs, Seattle Children’s Hospital, and principle investigator of the Medtronic ...

Home September 28, 2021
Home
Illustration of the Watchman transcatheter left atrial appendage (LAA) occluder being  deployed into the LAA. FDA is concerned about higher rates of LAA occlusion complications in women compared to men, prompting the FDA to send a letter to providers warning them on possible poor outcomes.
Feature | Left Atrial Appendage (LAA) Occluders

September 27, 2021 — Compared with men undergoing left atrial appendage occlusion (LAAO), women have a significantly ...

Home September 27, 2021
Home
Videos | Structural Heart

Dr. Neil Moat, MBBS, chief medical officer of Abbott's structural heart business, explains the latest advances in Abbott ...

Home September 20, 2021
Home
The U.S. Food and Drug Administration (FDA) has cleared the company's Portico with FlexNav transcatheter aortic valve replacement (TAVR) system to treat people with symptomatic, severe aortic stenosis who are at high or extreme risk for open-heart surgery. 
Feature | Structural Heart Occluders | By Dave Fornell, Editor

September 20, 2021 — Abbott announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Portico ...

Home September 20, 2021
Home
Subscribe Now